AR002990A1 - Una nueva combinacion de un inhibidor de reabsorcion de 5-ht y un antagonista 5-ht(1a), su uso para la preparacion de medicamentos, una formulacion farmaceutica que la comprende, un procedimiento para la preparacion de dicha combinacion y equipo que contiene dicha combinacion. - Google Patents
Una nueva combinacion de un inhibidor de reabsorcion de 5-ht y un antagonista 5-ht(1a), su uso para la preparacion de medicamentos, una formulacion farmaceutica que la comprende, un procedimiento para la preparacion de dicha combinacion y equipo que contiene dicha combinacion.Info
- Publication number
- AR002990A1 AR002990A1 ARP960102323A AR10232396A AR002990A1 AR 002990 A1 AR002990 A1 AR 002990A1 AR P960102323 A ARP960102323 A AR P960102323A AR 10232396 A AR10232396 A AR 10232396A AR 002990 A1 AR002990 A1 AR 002990A1
- Authority
- AR
- Argentina
- Prior art keywords
- combination
- preparation
- antagonist
- pharmaceutical formulation
- medicines
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 239000003420 antiserotonin agent Substances 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrane Compounds (AREA)
Abstract
La invención se refiere a una combinación de un primer componente (a) que es un inhibidor de reabsorción de 5-HT y un segundo componente (b) que es elantagonista selectivo 5-HT(1A) que tiene la fórmula general (I), en la cual R1 es n-propilo ocic lobutilo; R2 es isopropilo, butilo terciario, ciclobutilo,ciclopentilo o ciclohexilo; R3 es hidrógeno; R4 es hidrógeno o metilo; como enantiómero (R) en forma de una base libre o de sus sales farmacéuticamenteaceptables; la preparación delas mis mas; las formulaciones farmacéuticas que contienen dicha combinación, el uso y método de tratamiento de desórdenesafectivos tales como depresión, ansiedad y desorden compulsivo obsesivo (OCD) con dicha combinación, así como también unequipo que contiene dichacombinación, su uso para preparar medicamentos, una formulación farmacéutica que la comprende, un procedimiento para la preparación de dicha combinacióny un equipo que contiene dicha combinación.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9501567A SE9501567D0 (sv) | 1995-04-27 | 1995-04-27 | A new combination |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR002990A1 true AR002990A1 (es) | 1998-05-27 |
Family
ID=20398119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP960102323A AR002990A1 (es) | 1995-04-27 | 1996-04-25 | Una nueva combinacion de un inhibidor de reabsorcion de 5-ht y un antagonista 5-ht(1a), su uso para la preparacion de medicamentos, una formulacion farmaceutica que la comprende, un procedimiento para la preparacion de dicha combinacion y equipo que contiene dicha combinacion. |
Country Status (29)
| Country | Link |
|---|---|
| US (5) | US5962514A (es) |
| EP (1) | EP0822813B1 (es) |
| JP (1) | JPH11504037A (es) |
| KR (1) | KR100419810B1 (es) |
| CN (1) | CN1102386C (es) |
| AR (1) | AR002990A1 (es) |
| AT (1) | ATE216579T1 (es) |
| BR (1) | BR9608252A (es) |
| CA (1) | CA2218181A1 (es) |
| CZ (1) | CZ335697A3 (es) |
| DE (1) | DE69620878T2 (es) |
| DK (1) | DK0822813T3 (es) |
| EE (1) | EE03553B1 (es) |
| ES (1) | ES2175089T3 (es) |
| HU (1) | HUP9801946A3 (es) |
| IL (1) | IL117988A0 (es) |
| IS (1) | IS1821B (es) |
| NO (1) | NO317057B1 (es) |
| NZ (1) | NZ306602A (es) |
| PL (1) | PL183997B1 (es) |
| PT (1) | PT822813E (es) |
| RU (1) | RU2183955C2 (es) |
| SE (1) | SE9501567D0 (es) |
| SK (1) | SK282060B6 (es) |
| TR (1) | TR199701254T1 (es) |
| TW (1) | TW458777B (es) |
| WO (1) | WO1996033710A1 (es) |
| YU (1) | YU25696A (es) |
| ZA (1) | ZA962982B (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9501567D0 (sv) * | 1995-04-27 | 1995-04-27 | Astra Ab | A new combination |
| SE9703374D0 (sv) * | 1997-09-18 | 1997-09-18 | Astra Ab | A new combination |
| WO1999061014A2 (en) * | 1998-05-28 | 1999-12-02 | Sepracor Inc. | Compositions and methods employing r(-) fluoxetine and other active ingredients |
| SE9803155D0 (sv) * | 1998-09-16 | 1998-09-16 | Astra Ab | A new composition |
| SE9803156D0 (sv) * | 1998-09-16 | 1998-09-16 | Astra Ab | A new composition |
| SE9803157D0 (sv) * | 1998-09-16 | 1998-09-16 | Astra Ab | A new composition |
| SE9803158D0 (sv) * | 1998-09-16 | 1998-09-16 | Astra Ab | A new composition |
| AR021155A1 (es) * | 1999-07-08 | 2002-06-12 | Lundbeck & Co As H | Tratamiento de desordenes neuroticos |
| UA77650C2 (en) * | 1999-12-06 | 2007-01-15 | Lundbeck & Co As H | Use of serotonin reuptake inhibitor in combination with deramcyclane |
| US6331233B1 (en) | 2000-02-02 | 2001-12-18 | Honeywell International Inc. | Tantalum sputtering target with fine grains and uniform texture and method of manufacture |
| WO2002030405A2 (en) | 2000-10-13 | 2002-04-18 | Neurosearch A/S | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance |
| US20030185754A1 (en) * | 2001-01-16 | 2003-10-02 | Genset, S.A. | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists |
| US20030166554A1 (en) * | 2001-01-16 | 2003-09-04 | Genset, S.A. | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists |
| JP2004527551A (ja) * | 2001-05-01 | 2004-09-09 | ハー・ルンドベック・アクチエゼルスカベット | エナンチオ純粋なエスシタロプラムの使用方法 |
| US7034059B2 (en) | 2001-07-02 | 2006-04-25 | Sepracor Inc. | Methods of using norfluoxetine |
| US6855735B2 (en) | 2002-03-20 | 2005-02-15 | Temple University Of The Commonwealth System Of Higher Education | Ketamine treatment of restless legs syndrome |
| AU2003256430A1 (en) * | 2002-08-15 | 2004-03-03 | Wyeth | AGONISM OF THE 5HT2a RECEPTOR FOR TREATMENT OF THERMOREGULATORY DYSFUNCTION |
| US20050032873A1 (en) * | 2003-07-30 | 2005-02-10 | Wyeth | 3-Amino chroman and 2-amino tetralin derivatives |
| US7695601B2 (en) * | 2006-05-09 | 2010-04-13 | The United States Of America As Represented By The Secretary Of The Army | Electrochemical test apparatus and method for its use |
| US20080033050A1 (en) | 2006-08-04 | 2008-02-07 | Richards Patricia Allison Tewe | Method of treating thermoregulatory disfunction with paroxetine |
| US20160154928A1 (en) * | 2013-07-12 | 2016-06-02 | Immuneering Corporation | Systems, methods, and environment for automated review of genomic data to identify downregulated and/or upregulated gene expression indicative of a disease or condition |
| US11491136B2 (en) * | 2017-02-14 | 2022-11-08 | Research Triangle Institute | Proline-based neuropeptide FF receptor modulators |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4698342A (en) * | 1985-07-16 | 1987-10-06 | Serotonin Industries Of Charleston | Method and compositions for controlling pain, depression and sedation |
| US5616610A (en) * | 1989-12-22 | 1997-04-01 | Astra Aktiebolag | (R)-5-carbamoyl-8-fluoro-3-N,N-disubstituted-amino-3,4-dihydro-2H-1-benzopyrans |
| US5420151A (en) * | 1989-12-22 | 1995-05-30 | Aktiebolaget Astra | Chroman derivatives |
| SE9501567D0 (sv) * | 1995-04-27 | 1995-04-27 | Astra Ab | A new combination |
-
1995
- 1995-04-27 SE SE9501567A patent/SE9501567D0/xx unknown
-
1996
- 1996-04-15 ZA ZA962982A patent/ZA962982B/xx unknown
- 1996-04-15 TW TW085104481A patent/TW458777B/zh not_active IP Right Cessation
- 1996-04-21 IL IL11798896A patent/IL117988A0/xx not_active IP Right Cessation
- 1996-04-23 RU RU97119427/14A patent/RU2183955C2/ru active
- 1996-04-23 TR TR97/01254T patent/TR199701254T1/xx unknown
- 1996-04-23 EE EE9700245A patent/EE03553B1/xx not_active IP Right Cessation
- 1996-04-23 AT AT96912370T patent/ATE216579T1/de not_active IP Right Cessation
- 1996-04-23 KR KR1019970707592A patent/KR100419810B1/ko not_active Expired - Fee Related
- 1996-04-23 EP EP96912370A patent/EP0822813B1/en not_active Expired - Lifetime
- 1996-04-23 WO PCT/SE1996/000526 patent/WO1996033710A1/en not_active Ceased
- 1996-04-23 HU HU9801946A patent/HUP9801946A3/hu unknown
- 1996-04-23 SK SK1429-97A patent/SK282060B6/sk unknown
- 1996-04-23 JP JP8532425A patent/JPH11504037A/ja not_active Ceased
- 1996-04-23 BR BR9608252A patent/BR9608252A/pt not_active Application Discontinuation
- 1996-04-23 CN CN96194810A patent/CN1102386C/zh not_active Expired - Fee Related
- 1996-04-23 NZ NZ306602A patent/NZ306602A/en unknown
- 1996-04-23 CZ CZ973356A patent/CZ335697A3/cs unknown
- 1996-04-23 DK DK96912370T patent/DK0822813T3/da active
- 1996-04-23 ES ES96912370T patent/ES2175089T3/es not_active Expired - Lifetime
- 1996-04-23 DE DE69620878T patent/DE69620878T2/de not_active Expired - Fee Related
- 1996-04-23 PT PT96912370T patent/PT822813E/pt unknown
- 1996-04-23 US US08/640,896 patent/US5962514A/en not_active Expired - Fee Related
- 1996-04-23 CA CA002218181A patent/CA2218181A1/en not_active Abandoned
- 1996-04-23 PL PL96323083A patent/PL183997B1/pl unknown
- 1996-04-25 AR ARP960102323A patent/AR002990A1/es not_active Application Discontinuation
- 1996-04-26 YU YU25696A patent/YU25696A/sh unknown
-
1997
- 1997-10-09 IS IS4585A patent/IS1821B/is unknown
- 1997-10-24 NO NO19974921A patent/NO317057B1/no unknown
-
1999
- 1999-07-09 US US09/351,071 patent/US6184219B1/en not_active Expired - Fee Related
- 1999-07-09 US US09/349,590 patent/US6184218B1/en not_active Expired - Fee Related
- 1999-07-09 US US09/351,069 patent/US6169098B1/en not_active Expired - Fee Related
- 1999-07-09 US US09/351,070 patent/US6172105B1/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR002990A1 (es) | Una nueva combinacion de un inhibidor de reabsorcion de 5-ht y un antagonista 5-ht(1a), su uso para la preparacion de medicamentos, una formulacion farmaceutica que la comprende, un procedimiento para la preparacion de dicha combinacion y equipo que contiene dicha combinacion. | |
| UY27740A1 (es) | Nuevos compuestos | |
| ES2160640T3 (es) | Nuevos (r)-5-carbamoil-8-fluoro-3-amino disustituido en n,n-3,4-dihidro-2h-1-benzopiranos. | |
| UY28150A1 (es) | Agentes terapeuticos | |
| UY28215A1 (es) | Quinazolinas utiles como moduladores de canales iónicos | |
| CU23167A3 (es) | Inhibidores de la recaptacion de monoaminas para el tratamiento de trastornos del snc | |
| ECSP055738A (es) | PROCESO ENANTIOSELECTIVO PARA LA PREPARACIÓN DE AMBOS ENANTIÓMEROS DE 10,11-DIHIDRO-10-HIDROXI-5H-DIBENZ-[b,f]-AZEPIN-5-CARBOXAMIDA Y SUS NUEVAS FORMAS DE CRISTAL | |
| CO4810373A1 (es) | Compuestos azapoliciclicos condensados con arilo | |
| GT199800046A (es) | Compuestos de pirazina. | |
| UY27872A1 (es) | Inhibidores de caspasa y usos de los mismos. | |
| DK1697370T3 (da) | Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer | |
| BRPI0212733B8 (pt) | composição farmacêutica compreendendo composto inibidor da recaptação de serotonina, e, uso do mesmo | |
| CL2007002450A1 (es) | Forma polimorfica i del enantiomero levogiro o dextrogiro de modafinilo; su procedimiento de preparacion; y composicion farmaceutica que los comprende (divisional solicitud 2693-03). | |
| DK1506185T3 (da) | Forbindelser og deres anvendelse som 5-HT-inhibitorer | |
| CL2008001465A1 (es) | Compuestos derivados de [2,1,3]benzoxadiazol-5-carboxamidas, moduladores de los receptores ampa; composiciones farmacéuticas; y su uso en el tratamiento de afecciones hipoglutamatérgicas, trastornos cognitivos, enfermedad de parkinson, adhd, síndrome de rett, depresión respiratoria, síndrome x frágil y enfermedad de alzheimer. | |
| PA8525001A1 (es) | Compuestos de 1,4-dihidropiridina como antagonistas de bradicinina | |
| UY26924A1 (es) | Derivados de fenoxibencilamina como ssri | |
| MX9605218A (es) | Amidas aciclicas y ciclicas novedosas como mejoradores de liberacion de neurotransmisores. | |
| BR0308133A (pt) | Forma polimórfica cristalina de cloridrato de irinotecan | |
| CO5611124A2 (es) | Derivados de benzofurano substituidos utiles en el tratamiento de desordenes hiper-proliferativos | |
| ECSP056192A (es) | 3-fluoro-piperidinas como antagonistas de nmda/nr2b | |
| AR029461A1 (es) | Derivados de 4-fenil-1-piperazinilo, - piperidinilo y -tetrahidropiridilo , composiciones farmaceuticas que los comprenden y el uso de los mismos para la fabricacion de un medicamento | |
| AR035818A1 (es) | Fenil-heterociclil-eteres con actividad como inhibidores selectivos de recaptacion de serotonina, composiciones farmaceuticas y su uso en la fabricacion de medicamentos | |
| BR9916807A (pt) | Antagonistas de 5ht1 para terapia antidepressiva | |
| ES2189072T3 (es) | Nuevo benzo-cicloalquenos heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |